PR Newswire
LAS VEGAS, Feb. 23, 2026
The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 (Marea Therapeutics), Paltusotine (Crinetics Pharmaceuticals), CAM2029 (Camurus AB), and others, and increasing awareness among care providers and caregivers.
LAS VEGAS, Feb. 23, 2026 /PRNewswire/ — Recently published Acromegaly Market Insights report includes a comprehensive understanding of current treatment practices, acromegaly emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Acromegaly Market Summary
- The total acromegaly treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounts for the largest market size of acromegaly, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
- The total diagnosed prevalent cases of acromegaly in the US were ~27K in 2025. These numbers are expected to increase by 2036.
- Leading acromegaly companies, such as Crinetics Pharmaceuticals, Camurus AB, Alexion Pharmaceuticals, Debiopharm International SA, Marea Therapeutics, and others, are developing new acromegaly treatment drugs that can be available in the acromegaly market in the coming years.
- The promising acromegaly therapies in clinical trials include Paltusotine, CAM2029, ALXN2420, Debio 4126, MAR002, and others.
Discover what will the market share of acromegaly therapies @ https://www.delveinsight.com/sample-request/acromegaly-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Acromegaly Market
- Rising Acromegaly Prevalence: Acromegaly occurs in approximately 50-70 people per million per year. This increase in prevalence leads to increased R&D activities and more patients opting for treatment in the future.
- Advancing Diagnostic Tools for Early Acromegaly Detection: One of the major opportunities is exploring the advancement of diagnostic tools or methods for the early detection of acromegaly in the affected patient pool.
- Opportunities in the Acromegaly Treatment Landscape: There is potential in the acromegaly treatment landscape for drugs with improved clinical profiles and for the development of biomarker-based therapy (precision medicine) tailored to patients’ specific characteristics to improve overall patient outcomes.
- Launch of Emerging Acromegaly Therapies: The dynamics of the acromegaly market are expected to change in the coming years due to the launch of emerging therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 (Marea Therapeutics), Paltusotine (Crinetics Pharmaceuticals), CAM2029 (Camurus AB), and others.
Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, commented that the shift toward oral medications is driving the acromegaly market, with paltusotine further advancing this trend. Additionally, CAM2029’s once-monthly, ready-to-use injection pen offers patients convenient self-administration, reducing their treatment burden.
Acromegaly Market Analysis
- Treatment options for acromegaly include surgical removal of the pituitary tumor, radiation therapy, and medications to control growth hormone production.
- Early diagnosis and treatment can improve or reverse some symptoms, although long-standing physical changes may persist.
- Several approved therapies for acromegaly, including MYCAPSSA (Chiesi Farmaceutici), PALSONIFY (Crinetics Pharmaceuticals/Sanwa Kagaku Kenkyusho), OCZYESA (Camurus AB, approved in the EU), and SIGNIFOR LAR (Recordati), are currently available.
- Pharmaceutical developers are actively developing innovative modalities to address unmet needs in the treatment of acromegaly.
- Investigational therapies include Debio 4126 (Debiopharm International SA), ALXN2420 (Alexion Pharmaceuticals), MAR002 (Marea Therapeutics), and others.
Acromegaly Competitive Landscape
Some of the products under development for the treatment of acromegaly include Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 (Marea Therapeutics), Paltusotine (Crinetics Pharmaceuticals), CAM2029 (Camurus AB), and others.
Debiopharm International SA’s Debio 4126 is a next-generation, long-acting octreotide formulation intended for intramuscular injection once every three months. Early clinical findings, supported by strong pharmacokinetic modeling, indicate prolonged octreotide release, stable suppression of Insulin-like Growth Factor 1 (IGF-1), and a safety profile similar to that of existing somatostatin analogs (SSAs), providing a solid foundation for advancing to Phase III development.
AstraZeneca’s ALXN2420 is an emerging small-peptide antagonist of the Growth Hormone Receptor (GHR), being developed as an adjunct therapy to SSAs to achieve deeper IGF-1 suppression and normalization. The molecule binds to human GHR and blocks growth hormone-mediated activation in vitro. In animal studies, administration of ALXN2420 led to marked reductions in IGF-1 and was associated with decreased growth in juvenile rats. Notably, when combined with an SSA, ALXN2420 produced an additive reduction in IGF-1. The therapy is currently in Phase II testing for acromegaly.
Marea Therapeutics’ MAR002 is a highly potent, selective, long-acting allosteric monoclonal antibody that antagonizes the Growth Hormone Receptor and is being developed for acromegaly treatment. Its in vivo pharmacokinetic and pharmacodynamic profiles are consistent with those of an extended-half-life human antibody, supporting infrequent subcutaneous dosing in clinical use. These properties highlight its potential to deliver effective and convenient treatment for patients with acromegaly.
The anticipated launch of these emerging therapies are poised to transform the acromegaly market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the acromegaly market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the best acromegaly drugs by market share @ Acromegaly Drugs Market
Recent Developments in the Acromegaly Market
- In January 2026, Camurus announced that the US FDA had accepted for review the company’s resubmission of the New Drug Application (NDA) for OCLAIZ for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 10 June 2026.
- In January 2026, Marea Therapeutics announced positive topline results from its first-in-human Phase I study of MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR) for the treatment of acromegaly.
- In December 2025, Debiopharm announced that the first patient had been randomized in the Phase III (OXTEND-03) clinical trial for adults with acromegaly who are currently maintained onsomatostatin analogs.
- In August 2025, Marea Therapeutics announced that the first participant had been enrolled in its Phase I study evaluating MAR002 for the treatment of acromegaly.
What is Acromegaly?
Acromegaly is a rare hormonal disorder that occurs when the body produces too much growth hormone, usually due to a benign tumor on the pituitary gland. This excess hormone causes tissues, bones, and organs to grow larger than normal over time. People with acromegaly often develop enlarged hands and feet, changes in facial features such as a protruding jaw or enlarged nose, and symptoms like joint pain, headaches, and fatigue. If left untreated, the condition can lead to serious health complications, including heart disease and diabetes, but early diagnosis and treatment can help manage symptoms and prevent long-term problems.
Acromegaly Epidemiology Segmentation
The acromegaly epidemiology section provides insights into the historical and current acromegaly patient pool and forecasted trends for the leading markets. In the US, acromegaly diagnosed prevalent cases, based on origin, accounted for 95% pituitary tumors and 5% non-pituitary tumors.
The acromegaly treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Total Diagnosed Prevalent Cases of Acromegaly
- Tumor Origin-specific Diagnosed Prevalent Cases of Acromegaly
- Gender-specific Diagnosed Prevalent Cases of Acromegaly
- Tumor Size-specific Diagnosed Prevalent Cases of Acromegaly
- Total Treated Cases of Acromegaly
Acromegaly Market Forecast Report Metrics
Details
Study Period
2022-2036
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and
Japan].
Acromegaly Epidemiology Segmentation Total Diagnosed Prevalent Cases of Acromegaly, Tumor Origin-specific Diagnosed Prevalent Cases
of Acromegaly, Gender-specific Diagnosed Prevalent Cases of Acromegaly, Tumor Size-specific
Diagnosed Prevalent Cases of Acromegaly, and Total Treated Cases of Acromegaly
Key Acromegaly Companies Crinetics Pharmaceuticals, Camurus AB, Alexion Pharmaceuticals, Debiopharm International SA,
Marea Therapeutics, Amryt Pharma, Chiesi Farmaceutici, Recordati, Sanwa Kagaku Kenkyusho, and
others
Key Acromegaly Therapies Paltusotine, CAM2029, ALXN2420, Debio 4126, MAR002, MYCAPSSA, SIGNIFOR LAR, PALSONIFY, and others
Scope of the
Acromegaly
Market Report
- Therapeutic Assessment: Acromegaly current marketed and emerging therapies
- Acromegaly Market Dynamics: Key Market Forecast Assumptions of Emerging Acromegaly Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Acromegaly Market Access and Reimbursement
Download the report to understand what are novel biomarkers in acromegaly @ Acromegaly Market Forecast
Table of Contents
1
Acromegaly Market Key Insights
2
Acromegaly Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Methodology
6
Acromegaly Market Overview at a Glance
6.1 Clinical Landscape Analysis (By Phase, RoA, and Molecule Type)
6.2 Market Share (%) Distribution by Therapies of Acromegaly in 2025 in
the 7MM
6.3 Market Share (%) Distribution by Therapies of Acromegaly in 2036 in
the 7MM
7
Disease Background and Overview
7.1
Introduction
7.2
Causes
7.3
Diagnosis
8
Treatment and Management
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumption and Rationale of Acromegaly: The 7MM Analysis
9.3
Total Diagnosed Prevalent Cases of Acromegaly in the 7MM
9.4
The United States
9.4.1 Total Diagnosed Prevalent Cases of Acromegaly in the United States
9.4.2 Tumor Origin-specific Diagnosed Prevalent Cases of Acromegaly in the
United States
9.4.3 Gender-specific Diagnosed Prevalent Cases of Acromegaly in the
United States
9.4.4 Tumor Size-specific Diagnosed Prevalent Cases of Acromegaly in the
United States
9.4.5
Total Treated Cases of Acromegaly in the United States
9.5
EU4 and the UK
9.6
Japan
10
Acromegaly Patient Journey
11
Marketed Acromegaly Therapies
11.1
Key Cross Competition
11.2 Paltusotine (PALSONIFY): Crinetics Pharmaceuticals and Sanwa Kagaku
Kenkyusho
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Analyst’s View
11.3
CAM2029 (OCZYESA): Camurus AB
List to be continued…
12
Emerging Acromegaly Therapies
12.1
Key Cross Competition
12.2
MAR002: Marea Therapeutics
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trials Information
12.2.4
Safety and Efficacy
12.2.5
Analyst’s Views
12.3
Debio 4126: Debiopharm International SA
List to be continued in the report….
13
Acromegaly Market: 7MM Analysis
13.1
Key Findings
13.2
Acromegaly Market Outlook
13.3
Conjoint Analysis
13.4
Key Market Forecast Assumptions
13.5
Total Market Size of Acromegaly in the 7MM
13.6
Market Size of Acromegaly by Therapies in 7MM
13.7
The United States Acromegaly Market Size
13.7.1
Total Market Size of Acromegaly in the United States
13.7.2 Market Size of Acromegaly by Therapies in the United States
13.8
EU4 and the UK Acromegaly Market Size
13.9
Japan Acromegaly Market Size
14
Acromegaly Market Unmet Needs
15
Acromegaly Market SWOT Analysis
16
Key Opinion Leaders’ Views on Acromegaly
17
Acromegaly Market Access and Reimbursement
17.1
The United States
17.2
In EU4 and the UK
17.3
Japan
17.4 Summary and Comparison of Market Access and Pricing Policy
Developments in 2025
17.5
Market Access and Reimbursement of Acromegaly
18
Acronyms and Abbreviations
19
Bibliography
20
Acromegaly Market Report Methodology
Related Reports
Acromegaly Clinical Trial Analysis
Acromegaly Pipeline Insight
– 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acromegaly companies, including Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork, and others.
JAK Inhibitors Market
JAK Inhibitors
Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.
Growth Hormone Deficiency Market
Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key growth hormone deficiency companies, including Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others.
Adult Growth Hormone Deficiency Market
Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adult growth hormone deficiency companies, including Novo Nordisk, Ascendis Pharma, among others.
Pediatric Growth Hormone Deficiency Market
Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric growth hormone deficiency companies, including TJ Biopharma, Lumos Pharma, SCOHIA PHARMA, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/acromegaly-market-poised-for-significant-expansion-during-the-forecast-period-20262036-as-new-treatment-options-emerge–delveinsight-302694385.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…